ABSTRACT
METHODS
A retrospective review of the ECMO database at the SPCS was undertaken. Our inclusion criteria encompassed all neonatal and pediatric patients (<16 years of age) who underwent VA ECMO following cardiac surgery between January 2011 and October 2016 in Scotland.
Patients were identified from the ECMO database; further clinical details were obtained from the clinical database, "HeartSuite™" database, and reviewed by two assessors (MK and MD). We then risk stratified the patients using the Risk Adjustment for Congenital Heart Surgery (RACHS) score based on the type of morphology and operation.
We divided the patients into three subgroups based on ECMO timing: "end-of-case" where patients had ECMO support initiated in the operating theater, following cardiac surgery; "E-CPR" where patients who sustained cardiorespiratory arrest were receiving ongoing external and/or internal cardiac massage when ECMO was initiated; and patients in whom ECMO was instituted during their PICU or ward stay because of "failing maximal medical therapy." As with many other programs, we currently do not have a protocol defining a set inotropic support threshold to define "failing maximal medical therapy." The decision as of whether or not the patient has reached the ceiling on medical therapy is made on a case-by-case basis judged by the multidisciplinary team.
We obtained follow-up (FU) data on patient's survival and quality of life following institution of postoperative VA ECMO.
Statistical analysis
We performed univariate analysis using the Fisher's exact test to address the small patient population in our cohort [ Table 1 ]. We utilized the Kaplan-Meier curve to ascertain survival. We used the log-rank test to determine statistical significance of the effect of ECMO duration and outcome to address the skew in our data and the effect of heterogeneity in our patient population. The primary outcome measure was to determine the rate of survival to hospital discharge in postcardiotomy VA ECMO following pediatric cardiac surgery. The secondary outcome measure was to identify most likely factors leading to a favorable outcome, i.e., survival to hospital discharge and intermediate-term survival.
RESULTS
We identified 66 (4% of the total 1594 pediatric cardiac surgical cases) patients in the study period who met the inclusion criteria. In our patient cohort, 72% (n = 49) had had elective surgery and the remainder underwent urgent/emergency surgery (n = 17, 28%).
INTRODUCTION
Since its inception in 1973, [1] extracorporeal membrane oxygenation (ECMO) has been a valuable tool in salvaging patients who develop cardiorespiratory failure after cardiac surgery. [2, 3] ECMO has been utilized following both adult [4, 5] and pediatric cardiac surgeries [3, 6] with encouraging results. As much as 3.2%-8.4% of children undergoing congenital cardiac surgery may require ECMO support in the postoperative period for cardiorespiratory failure. [7] [8] [9] The main utility of veno-arterial (VA) ECMO is to provide cardiac output while "resting" the heart following the operative insult, to allow time for recovery of function and "bridge to recovery." [10, 11] In smaller proportion of patients in whom adequate functional recovery is not achieved, ECMO can be used to support the circulation until alternatives are instituted including ventricular assist device (VAD), orthotopic heart transplant (OHT), or end-of-life care. [12] [13] [14] Among other indications, VA ECMO can also be utilized to temporize and stabilize preoperative patients in cardiorespiratory failure to "bridge to cardiac surgery." [15] Due to the heterogeneity of conditions and patient factors, the indications and timing of VA ECMO in postcardiotomy patients are based on empirical clinical judgment. Reversibility of the underlying etiology of circulation failure is, however, a key to a successful outcome. [7] Despite its many advantages, VA ECMO is associated with major complications [4, 5, 16, 17] and it carries a significant cost burden; [18, 19] therefore, the risk-benefit ratio should be weighed before institution of this salvage strategy.
The most common clinical scenarios in which VA ECMO is utilized following pediatric cardiac surgery are as follows: following a cardiac operation who fails to wean off from cardiopulmonary bypass (CPB) or "end-of-case" ECMO to support cardiorespiratory failure, [1, 2, 7, 14] following unanticipated postoperative cardiac arrest (i.e., extracorporeal cardiopulmonary resuscitation [E-CPR]), [1, 14, 20, 21] or for circulatory support [7, 14, 22] in patients who develop circulatory failure despite "failing maximal medical therapy."
The Scottish Pediatric Cardiac Services (SPCS) is based on the Royal Hospital for Children (RHC) in Glasgow, a tertiary referral pediatric hospital, which provides services to the Scottish population of 5.2 million. [23] The unit performs approximately 320 major pediatric cardiac surgeries and 180 catheter-based interventions per year. [23] The pediatric Intensive Care Unit (PICU) has 22 beds, 8 of which are dedicated to cardiac surgery. [24] RHC, Glasgow, is one of the six designated pediatric respiratory ECMO centers in the UK. [24, 25] In this study of the SPCS unit, we aimed to identify determinants of survival in postcardiotomy VA ECMO in the clinical scenarios delineated above.
CPB and XC times. The survival rate fell when CPB times of 400 min and XC times of 120 min were breached; these findings did not reach statistical significance on univariate analysis (P = 0.201).
In our study, 98 patients underwent full repair or shunt placement for TOF. Eleven (11%) patients were supported with ECMO of which 6 (55%) survived. Of the five who died, three suffered necrotizing enterocolitis (NEC). We have since developed a novel "high-risk" nutrition pathway and have reduced the risk of this catastrophic complication postcardiac surgery. [26, 27] In the study period, a total of 64 patients underwent arterial switch operation for TGA. Fourteen (22%) patients required VA ECMO support, of which seven survived the ordeal. One patient required mechanical ventilation and hemofiltration preoperatively and required "E-CPR" ECMO postoperatively. A total of 5 of the 14 TGA patients supported with ECMO were supported in an "E-CPR" state.
Age on extracorporeal membrane oxygenation versus survival
T h e a g e r a n g e i n o u r p a t i e n t c o h o r t was <1-5475 days (mean = 635 days, median = 60 days). We subcategorized the patients by age [ Figure 1 ]. The majority of the children supported with ECMO in the postoperative phase were <6 months of age. This group had higher mortality rates compared to older age groups though this did not reach statistical significance (P = 0.502).
Timing of extracorporeal membrane oxygenation versus survival
The majority of patients had ECMO deployed in the operating theater following cardiac surgery, 36 patients (55%); E-CPR in 22 (33%) patients; and ECMO deployed in PICU due to "failed maximal medical therapy" being least common, eight patients (12%). Figure 2 illustrates the patient outcome based on ECMO timing.
Extracorporeal membrane oxygenation duration and survival
The relationship between ECMO duration (days on support) and survival was investigated [ Figure 3 ]. We identified a trend toward worsening survival rate with increasing ECMO duration.
There were no survivors when postoperative cardiac ECMO support exceeded 10 days in duration, among which only one patient was transferred to transplant center for VAD implantation but later died (see below). Univariate analysis, however, did not yield a statistical significance between ECMO support duration and survival [ Figure 4 ].
Survival rate and follow-up
Forty-six patients (70%) survived to ECMO decannulation. However, following ECMO decannulation, 16 (25%) died
Operation-related factors versus survival
The type of operations leading to VA ECMO was diverse. We have risk stratified the patients based on the morphology and the type of operations using the RACHS score [ Table 1 ]. However, the most common pathologies leading to postoperative VA ECMO were transposition of great arteries (TGAs), hypoplastic left heart syndrome, and tetralogy of Fallot (TOF).
We assessed the correlation between the duration of CPB and cross-clamp (XC) times for each operation with the likelihood of needing postcardiotomy VA ECMO and survival. Not surprisingly, we noted an increasing utility of VA ECMO support and mortality associated with longer 
Extracorporeal membrane oxygenation cannulation
In our patient cohort, 59 (89%) patients had had central ECMO and only 7 (11%) had peripheral ECMO cannulation. Among the elective "end-of-case" ECMO patients, 32 (88% of the total "end-of-case" ECMO group) had central ECMO and only 4 (12% of "end of case" ECMO group) patients had had peripheral ECMO. Of the E-CPR subgroup, all but one were cannulated centrally, this being the most expedient route of establishing ECMO in this patient group. Finally, one other patient underwent emergency ECMO following re-admission almost 1 year after her original mitral valve repair due to severe mitral valve stenosis and low cardiac output.
Of the "failing maximal medical therapy" cohort, 7 patients (88%) were cannulated centrally onto ECMO support and one patient had peripheral cannulation. Central ECMO cannulation tends to be the preferred option in patients <2 weeks postoperative as this was found to be the quickest and safest way of initiating ECMO support by the local surgical team.
Complications and extracorporeal membrane oxygenation
Major bleeding requiring re-exploration occurred in 24 (36%) patients. Eighteen (75%) patients were explored in the first 24 h. Six (25%) patients had no initial major bleeding but required exploration later on in the ECMO run for "latent bleeding." Overall survival rate to hospital discharge in the explored group was 12 (50%). Survival rates for early bleeding versus late bleeding were 61% and 17%, respectively.
Major neurological injury accounted for a significant proportion (23%, n = 15) of our patient cohort who received postcardiotomy VA ECMO, of whom only five survived to hospital discharge (P = 0.391).
A further serious complication was NEC and the need for laparotomy (18%, n = 12). Among our patient cohort, six (9%) patients required laparotomies. Two patients required two separate laparotomies for NEC. Of note, none of our patients who underwent laparotomy in the postoperative period survived to hospital discharge. We believe that these cases were caused by hypoperfusion of the gut associated with a low cardiac output state or poor venous drainage of the gut.
The incidence of renal failure requiring renal replacement therapy in our cohort was 17 (26%), of whom six patients survived to hospital discharge. None of the survivors required long-term dialysis after hospital discharge (P = 0.572).
The summary of the statistical analysis is tabulated in Table 2 .
Catheter-based interventions on extracorporeal membrane oxygenation
In our patient cohort, seven (11%) patients underwent cardiac catheter-based assessment and intervention. Four of these patients had catheterization, and interventions on ECMO included ballooning of pulmonary arteries or aorta, siting of pulmonary artery stents to alleviate elevated right ventricular pressures. Three patients had diagnostic catheterization only without intervention. Of note, four (6%) required return to the operating theater to address residual lesions. None of the patients who had cardiac catheterization survived.
DISCUSSION
The utility of VA ECMO in pediatric cardiac surgery has been increased in the past few years due in part to increasing complexity of congenital pathologies encountered. [28, 29] As there is currently no internationally agreed protocol for initiation of postcardiotomy VA ECMO for cardiorespiratory failure, the decision as of whether or not to institute this salvage, temporizing strategy is typically made on a case-by-case basis, based on the empirical judgment of the multidisciplinary team. [29] Presence of a reversible cardiac pathology is a strong indication for institution of VA ECMO. [6, 29] Furthermore, ECMO is costly and is associated with a significant rate of serious complications. [30, 31] Broadly speaking, there are three clinical scenarios in pediatric cardiac surgery where VA ECMO is applied. In theater, "end-of-case" ECMO, which denotes that VA ECMO is instituted when the child cannot be separated from CPB with favorable hemodynamic or physiological parameters. The other scenarios include sudden, unexpected cardiorespiratory arrest requiring CPR and resulting in the institution of VA ECMO, i.e., "E-CPR" and lastly deployment of ECMO postcardiac surgery for circulation despite "maximal medical therapy." [6] Gupta et al. [32] performed the largest study in the literature on this subject to date. In a multicenter study of 998 children from 37 centers in the USA, they reported 48.1% survival rate to hospital discharge. They identified that prolonged VA ECMO duration beyond 7 days increased the odds of mortality by 12% for every extra day on VA ECMO. [32] In another large study of 192 patients, Agarwal et al. [29] reported 41% survival rate to hospital discharge. They identified that late detection and correction of residual lesions while on VA ECMO conferred less chance of successful weaning from mechanical support and subsequent hospital discharge. [29] In an intermediate-sized study of 100 consecutive patients with refractory cardiorespiratory failure requiring VA ECMO, Alsoufi et al. [33] reported 37% rate to hospital discharge. They identified factors such as performing a postoperative angiogram, prolonged VA ECMO support, renal failure, nonnormalization of serum lactate, and elevated liver enzymes to increase the risk of mortality in such patients. [33] Shah et al. [28] in another intermediate-sized study of 84 patients reported 36.9% survival to hospital discharge. They identified high arterial serum lactate at the onset of ECMO (14.4 ± 7.5 mmol/L) and prolonged ECMO duration to be associated with mortality. [28] In another UK-based study, 53 patients required VA ECMO for refractory cardiorespiratory failure. Reported survival rate on long-term FU was 37.7%. They found prolonged ECMO duration, renal replacement therapy, neurological impairment, and bleeding complications as determinants of mortality in their study group. [6] Our patient cohort of 66 had an intermediate-term survival rate of 44% on FU, which is in keeping with the findings from several similar studies in the past. [7, [30] [31] [32] 34] In our group, 33% of patients had E-CPR, as compared with 22% in another UK study by Balasubramanian et al. [6] Despite this, Overall survival was not adversely affected by the higher proportion of E-CPR use. Although some studies suggest that ECMO instituted "early" or prior to cardiorespiratory arrest will carry a more favorable outcome, [1, 35] this needs to be balanced by the potential for "over-use" of ECMO in patients who may otherwise avoid ECMO completely. Ultimately, such questions of ECMO timing and indication can only be answered by an intention-to-treat analysis.
The occurrence of renal failure requiring dialysis while on ECMO is associated with a higher mortality compared with those patients who do not require renal support. One can speculate that either the requirement for dialysis denotes a higher risk group or dialysis in-of-itself can add additional complications. This question cannot be answered by this study. Over the recent years, we have moved to using continuous veno-venous hemofiltration in the majority of our cardiac ECMO patients, which we hope will provide a benefit to the patient.
About a third of our patients suffered severe bleeding complications requiring re-exploration while on VA ECMO. We identified a significant decline in survival once there is latent bleeding as compared to early bleeding. Since then, we developed unit policy to aggressively explore major bleeding. We withhold heparin until blood loss is <3 mL/kg/h.
We acknowledge that our study shows higher rates of central nervous system sequelae than what has been reported in large studies reporting neurological outcomes following "general" VA ECMO (10.9%) and the Extra-corporeal Life Support Organization registry. [36] However, the large volume data reporting neurological sequelae of 10.9% [36] pertain to all cases of ECMO (noncardiac surgical and postcardiotomy) and not solely postcardiotomy as is the case in our report. We believe that, in the context of postcardiotomy ECMO, there are other mitigating factors that could lead to higher rate of neurological injury, for example, the need for CPB in performing the original operation increases the risk of embolic and other neurological complications. [37] Of note in our cohort, 13 (87%) patients who sustained major neurological injury had CPB runs exceeding 400 min. The need for DHCA also increases the risk of generalized cerebral hypoperfusion and neurological injury. [38] To qualify the above point, a similar study to ours from another UK center by Balasubramanian et al. [6] reported similar rates of neurological sequelae of 19%. Alsoufi et al. [14] reported 17% rate of neurological injury and Gupta et al. in the largest study on the topic reported 10% stroke and 9% major seizure activity (it was unclear whether these were separate patient groups). The rate of E-CPR in our cohort was 33% (vs. 22% in the Balasubramanian et al's. study) leading to potentially greater cerebral hypoperfusion, which could be a mitigating factor for the higher rate of neurological sequelae in our study as seven (47%) of the total neurological sequelae in our study developed after E-CPR. This finding has led to the development of a novel "ECMO watcher" protocol in our institution to encourage the earlier use of ECMO and ensure the wider team is prepared should a patient have a clinical deterioration and require ECMO support. Our study has reaffirmed the finding that postcardiotomy VA ECMO has a definite survival benefit in pediatric cardiac surgery in a group of patients whom would have otherwise not survived without its use. However, institution of ECMO was associated with significant rate of severe complications. From our experience, it can be said that a key to a successful ECMO run is meticulous attention to hemostasis prior to transition onto VA ECMO. Hemostasis must be achieved while still on CPB. Once transitioned onto ECMO, blood products can then be administered to aid "nonsurgical bleeding." In our practice, we utilize two methods to transition from CPB onto ECMO; (i) complete wean from CPB, then administer protamine and blood products with latent transition to ECMO, (ii) immediate or almost immediate transition to ECMO from CPB. The use of each method would depend on hemodynamic stability of the patient. In patients where the predominant issue is ventilatory, one can opt for method (i). This method confers the advantage of heparin reversal prior to transitioning onto ECMO. Giving protamine on ECMO is not favored in our institution due to concern of thrombosis; however, it can be done but with great caution at smaller doses and also depending on the activated clotting time levels preprotamine.
In our experience, the problems encountered in premature transition from CPB to ECMO without adequate hemostasis include; (i) loss of volume in the ECMO circuit due to bleeding leading to multiple blood transfusions as well as ECMO flow instability. Bleedings while still on bypass can be sucked back into CPB circuit via pump suckers and transfused back to patients, therefore avoiding (or reducing need for) blood transfusion and its related complications and (ii) surgical hemostasis is more difficult while on ECMO, as surgical manipulation of the heart can disrupt the ECMO flow more easily.
While we do not follow an institutional protocol applied to place a patient ab initio onto ECMO post-CPB, we advocate careful judgment for each individual patient's hemodynamics after coming off CPB on the following principles; (i) If the hemodynamics are labile or there is difficultly in ventilation postrepair, time is spent in the operating theater to assess the trends of hemodynamics and evaluate the need of ECMO before returning to ICU, (ii) full correction of any residual surgical lesions is essential before placing patient on ECMO, and (iii) if longer time is anticipated for recovery, for example, with poor ventricular or respiratory function, arrhythmias (e.g., junctional ectopic tachycardia), and after all residual lesions are addressed, then CPB could be transitioned to ECMO more seamlessly.
We identified that postcardiotomy VA ECMO in younger infants, or those with a prolonged duration of VA ECMO, was the factor associated with a higher mortality rate. We found that mortality rate increased (albeit without statistical significance) with long CPB and XC times (see above). While this finding could reflect the general complexity of the operation and should not be interpreted in isolation as prognostic indicators, it raises the important question of whether the surgeon should persevere in correcting the pathological lesion at the expense of a higher CPB and XC times or "bail out" earlier to reduce these times, the answer to which fell out with the scope of our study. A policy of aggressive investigation, diagnosis, and management of residual lesions is key to a successful outcome to enable patients to be weaned off ECMO within several days of the initial surgery with no survivors in those supported on ECMO for over 10 days.
Limitations
Our study was limited by its retrospective nature, heterogeneity of the studied patient population, and limited number of patients. Our findings, although in keeping with the reported literature, did not reach statistical significance. Furthermore, in this study, we did not assess residual lesions and whether or not these were addressed in any subsequent operations. We regret that we did not have the data on "down time" prior to institution of E-CPR for this analysis as this could have explained our slightly higher rates of neurological sequelae.
CONCLUSIONS
A p p l i c a t i o n o f p o s t c a r d i o t o m y V A E C M O f o r cardiorespiratory failure has a definite survival benefit in a group of patients who would otherwise die. ECMO is expensive and carries significant rates of complications. Decisions surrounding indications and timing of this salvage modality remain a complicated and multidisciplinary decision and is made on an empirical case-by-case basis. The need for ECMO should be anticipated early, and elective ECMO should be instituted so as to prevent the need for E-CPR where possible. We found that end-of-case, in-theater ECMO carried better survival rates. Prolonged ECMO support had a direct correlation with mortality.
